PTO/SB/08b (04-09)

Approved for use through 05/31/2009. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO						Complete if Known			
AND SALL					Application Number	ation Number 10/785,497			
N	FOR	MATION [ISC	LOSURE	Filing Date	February	February 24, 2004		
***		MENT BY			First Named Inventor	Mark W. I	Mark W. Becker et al.		
0,	M		<i>,</i> , ,		Art Unit	1657			
	N _U s	se as many sheets	аѕ песе	issary)	Examiner Name	P.C. Mart	P.C. Martin		
Sheet	*		f	2		Attorney Docket Numbe	249.P2		
		MAN .		dupl					
		N.		U.S. PA	TEN	T DOCUMENTS			
Examiner Initials*	Cite No.1	Document Nu Number-Kind Oxde ²		Publication Date MM-DD-YYYY		Name of Patente Applicant of Cited Do		Bages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	AA*	US-5,591,85		01-07-1997	Alex	ander			
	AB*	US-5,656,745	AAAA	08-12-1997	Bisc	hofberger et al.			
	AC*	US-5,717,095	THE STREET	02-10-1998	Arm	illi et al.	A STATE OF THE STA		
	AD*	US-5,756,486	NAME OF THE OWNER, WHEN	05-26-1998	Alex	ander et al.			
	AE*	US-5,886,179	4	03-23-1999	Arim	nilli et al.			
	AF*	US-6,225,460		05-01-2001	Bisc	hofberger et al.			
	AG*	US-7,390,791		06 24-2008	Bec	keretal. 🥒			
	AH*	US-20020119	443	08-29 2002	Bec	ker et al.			
				N	<u></u>				
					A STATE OF THE STA				
					M				
		<u> </u>			ļ`	V			
ļ						/\			
	ļ				A STATE OF THE STA	1			
	ļ				A STATE OF THE STA	<u> </u>			
					1				

		FOB€i	GN PATENT	DOCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code (if known)	MM-DD-YYYY	Applicant of Oted Document	Or Relevant Figures Appear	Τ ⁶
	ВА	WO-0208241	01-31-2002	Gilead Sciences Inc et al.		
	вв	WO-9200988	01-23-1992	Bodor Nicholas S	:	
	:					
				No.		

		<i>f</i>		 	
Examiner	A		Date	M	
Signature			Considered	Marie Control	

^{*}EXAMINER: Initial if seference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the if W. ** CITE NO.: Those documents(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filling date under 35 U.S.C. 120. * Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ** Enter Office that issued the document, by the two setter code (WIPO Standard ST.3). ** For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ** Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ** Applicant is to place a sheck mark feer if English language Translation is attached.

PTO/SB/08b (04-09)

Approved for use through 05/31/2009. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/785,497 INFORMATION DISCLOSURE Filing Date February 24, 2004 STATEMENT BY APPLICANT Mark W. Becker et al. First Named Inventor Art Unit 1657 (Jse as many sheets as necessary) Examiner Name P.C. Martin 249.P2 Attorney Docket Number Sheet

duplicate

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the tem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(d), volume-issue number(s), publisher, city and/or country where published.	T 2
	CA	Beach et al. (1998) "Chemotherapeutic agents for human immuodefigiency virus infection: Mechanism of action, pharmacokinetics, metabolism, and adverse reactions," <i>Clinical Thereapeutics</i> 20(1):2-25	
	СВ	CAMP, N.P. et al. (1995) "Synthesis of Peptide Analogues Containing Phosphonamidate Methyl Ester Functionality: HIV-1 Proteinase Inhibitors Possessing Unique Cell Uptake Properties,"	
	СС	Cihlar et al. (2006) "Suppression of HIV-1 Protease Inhibitor Resistance by Phosphonate-mediated solvent anchoring, Journal of Molecular Biology 363(3):635-647	
	CD	Eddershaw et al. (2000) "ADME/PK as part of a retional approach to drug discovery" <i>Drug Discovery Today</i> 5(9):409-414	
	CE	FRANCHETTI, P., et al. (1998) "Potent and Selective Inhibitors of Human Immunodeficiency Virus Protease Structurally Related to L-94,746," Antiviral Chemistry & Chemotherapy 9(4):303-309	
	CF	GULICK (2003) "New Antiviral Drugs," Chrical Microbiology amd Infectious Diseases 9:186- 193	
	CG	Hoggard et al. (2002) "Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules," Current Opinion in Infectious Diseases 15(1):3-8	
	СН	Kiso et al. (1999) "Design of small peptidominetic NV-1 Protease Inhibitors and Prodrug Forms;" 6(5/6):275-281	
	СІ	Krise et al. (1996) "Prodrugs of Phosphates, Phospharetes, and Phosphinates," Advanced Drug Delivery Reviews 19(2):287-310	
**************************************	C1	Kubota et al. (1998) "Novel inhibitory effects of gamma-glutamylcysteine ethyl ester against human immunodeficier by virus type 1 production and propagation," <i>Antimicrobial Agents and Chemotherapy</i> 42(5):1200-1206	
	ск	Lee et al.(2002) 1 Vivo and In Vitro Characterization of GS 7340 an isopropylalaninyl phnyl ester prodrug of i enofovir: selective intracellular activation of GS 7340 leads to preferential distribution in imphatic tissues. 9th Conference of Retroviruses and Exporunistic infectioons, Abstract No. 3847	
	CL	Robbins of al. (1998) "Anti-Human Immunodeficieny Virus Activity and Cevular Metabolism of A Potential Prodrug of the Acyclic Nucleoside Phosphonate 9-R-(2-Phosphonomethoxypropyl) Adenile (PMPA), Bis(Isopropyloxymethylcarbonyl) PMPA" Antimicrobial Agents and Chemotherapy 42(3):612-617	
	CL	Zmra et al. (2000) "Uptake of pivaloyloxymethyl butyrate into leukemic esterase-catalyzed hydrolysis," Journal of Cancer Research and Clinical Oncology 126(12):693-698	

Examiner	AFF	Date		A. A
Signature 🌶	3	 Considered	<u> </u>	N. S.

Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

^{*}EXAMPRE: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for a partier filing date under 35 U.S.C. 120.